Stock Events

Stock Events

Anixa Biosciences 

€2.59
64
+€0.08+2.99% Monday 06:03

Statistics

Day High
2.59
Day Low
2.59
52W High
5
52W Low
2.22
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5JunExpected
Q4 2025
Next
-0.08
-0.07
-0.07
-0.07
Expected EPS
-0.06935927224999999
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CY71.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas similar to Anixa, including oncology, making it a direct competitor.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. is a global healthcare company that produces cancer treatments and vaccines, competing in the oncology and immunotherapy spaces like Anixa.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb operates in the biopharmaceutical field focusing on cancer, a key area for Anixa, making them competitors in developing treatments for various cancers.
AMGEN
AMGN
Mkt Cap178B
Amgen is a biotech company focusing on human therapeutics, including oncology and inflammation, areas where Anixa is also aiming to make significant contributions.
Pfizer
PFE
Mkt Cap149.77B
Pfizer is involved in the discovery, development, and manufacture of healthcare products including cancer treatments, directly competing with Anixa's focus areas.
Novartis
NVS
Mkt Cap279.67B
Novartis AG focuses on patented medicines for a range of diseases, including cancer, directly competing with Anixa in the oncology research and development space.
Roche
RHHBY
Mkt Cap328.49B
Roche Holding AG is a major player in pharmaceuticals and diagnostics with a strong focus on oncology, making it a competitor to Anixa in cancer research and treatment.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca PLC is a biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines, including for cancer, competing with Anixa.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson engages in the research and development, manufacture, and sale of a broad range of healthcare products, including cancer treatments, competing with Anixa.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions, including cancer, similar to Anixa's focus.

About

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Show more...
CEO
Dr. Amit Kumar Ph.D.
Employees
5
Country
United States
ISIN
US03528H1095

Listings

STU
DE
CY71.STU
MU
DE
CY71.MU
XNAS
US
ANIX
F
DE
CY71.F

0 Comments

Share your thoughts

FAQ

What is Anixa Biosciences stock price today?▼
The current price of CY71.MU is €2.59 EUR — it has increased by +2.99% in the past 24 hours. Watch Anixa Biosciences stock price performance more closely on the chart.
What is Anixa Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Anixa Biosciences stocks are traded under the ticker CY71.MU.
Is Anixa Biosciences stock price growing?▼
CY71.MU stock has fallen by -0.58% compared to the previous week, the month change is a +13.38% rise, over the last year Anixa Biosciences has showed a +6.82% increase.
When is the next Anixa Biosciences earnings date?▼
Anixa Biosciences is going to release the next earnings report on June 05, 2026.
What were Anixa Biosciences earnings last quarter?▼
CY71.MU earnings for the last quarter are -0.07 EUR per share, whereas the estimation was -0.08 EUR resulting in a +10.16% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Anixa Biosciences have?▼
As of May 06, 2026, the company has 5 employees.
In which sector is Anixa Biosciences located?▼
Anixa Biosciences operates in the Health & Wellness sector.
When did Anixa Biosciences complete a stock split?▼
Anixa Biosciences has not had any recent stock splits.
Where is Anixa Biosciences headquartered?▼
Anixa Biosciences is headquartered in San Jose, United States.